Previous studies investigating the infection risk in SLE have been prevalent cohort studies with small sample sizes. The current study is a large, retrospective, 1:5 matched, incident cohort study based on 25 years of administrative data of 2 million randomly selected Canadian citizens. The authors identified 5,169 confirmed incident SLE cases (mean age 47; 90% women), who were matched for age and sex with 25,845 non-SLE individuals. Outcome measures were first severe infection (defined by the need for professional medical care) after SLE onset, the number of severe infections, and infection-related death.
The results demonstrated that SLE patients had an 82% increased risk of developing a severe infection compared with their matched non-SLE counterparts. Furthermore, SLE patients had twice as many severe infections and a 61% increased risk of infection-related death. Mr Kai Zhao (Simon Fraser University, Canada) argued that early SLE patients often have higher disease activity and use more glucocorticoids, factors that could explain the increased risk of severe infections. He suggested that a tailored treatment, including increased use of immunosuppressants, could provide a solution for this problem. In addition, further analysis of infection type (bacterial, viral) might give more insight into how to tackle severe infections in SLE in the future.
- Zhao K, et al. Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: A population-based study. OP0043, EULAR 2021 Virtual Congress, 2–5 June.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Prognostic factors for minimal disease activity in early psoriatic arthritis revealed Next Article
Emerging therapies and future treatment directions in osteoarthritis »
« Prognostic factors for minimal disease activity in early psoriatic arthritis revealed Next Article
Emerging therapies and future treatment directions in osteoarthritis »
Table of Contents: EULAR 2021
Featured articles
COVID-19 Update
Rituximab or JAK inhibitors increase the risk of severe COVID-19
Updates on COVID-19 vaccines in patients with rheumatic disease
Immunomodulatory therapies for severe COVID-19: literature update
New Developments in Rheumatoid Arthritis
JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Remote management of RA is a feasible alternative for outpatient follow-up
TOVERA: Ultrasound is a promising biomarker of early treatment response
The risks of polypharmacy in RA
ABBV-3373: A potential new therapeutic agent for RA
JAK inhibitors and bDMARDs show comparable effectiveness
Spondyloarthritis: Progression in Therapies
SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis
Guselkumab efficacious in PsA patients with inadequate response to TNF inhibition
Faecal microbiota transplantation not effective in active peripheral PsA
Risankizumab meets primary and ranked secondary endpoints in PsA
Prognostic factors for minimal disease activity in early psoriatic arthritis revealed
Imaging in Large-Vessel Vasculitis
PET/CT is a reliable measure of disease activity in LVV, but does not predict future relapses
Ultrasound is useful for disease monitoring in giant cell arteritis
Prevention in Rheumatic Diseases
Air pollution predicts decreased response to biological treatment in rheumatic diseases
Passive smoking associated with an increased risk of RA
Gene-Environment Interaction in Gout
Gene-diet and gene-weight interactions associated with the risk of gout
What Is New in Systemic Lupus Erythematosus
Intensified treatment regimen of anifrolumab for lupus nephritis is promising
Systemic lupus erythematosus: increased risk of severe infection
Juvenile Idiopathic Arthritis and Osteoarthritis
Efficacy and safety of secukinumab in juvenile idiopathic arthritis
Emerging therapies and future treatment directions in osteoarthritis
Related Articles
July 21, 2022
New treatments in osteoarthritis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com